rs34557412
Positions:
Variant summary
Our verdict is Uncertain significance. Variant got 4 ACMG points: 5P and 1B. PM1PM5PP5BP4
The ENST00000261652.7(TNFRSF13B):c.310T>C(p.Cys104Arg) variant causes a missense change. The variant allele was found at a frequency of 0.00544 in 1,614,226 control chromosomes in the GnomAD database, including 32 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity,risk factor (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. C104Y) has been classified as Likely pathogenic.
Frequency
Genomes: 𝑓 0.0039 ( 4 hom., cov: 32)
Exomes 𝑓: 0.0056 ( 28 hom. )
Consequence
TNFRSF13B
ENST00000261652.7 missense
ENST00000261652.7 missense
Scores
10
3
6
Clinical Significance
Conservation
PhyloP100: 4.18
Genes affected
TNFRSF13B (HGNC:18153): (TNF receptor superfamily member 13B) The protein encoded by this gene is a lymphocyte-specific member of the tumor necrosis factor (TNF) receptor superfamily. It interacts with calcium-modulator and cyclophilin ligand (CAML). The protein induces activation of the transcription factors NFAT, AP1, and NF-kappa-B and plays a crucial role in humoral immunity by interacting with a TNF ligand. This gene is located within the Smith-Magenis syndrome region on chromosome 17. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 4 ACMG points.
PM1
In a disulfide_bond (size 11) in uniprot entity TR13B_HUMAN there are 5 pathogenic changes around while only 0 benign (100%) in ENST00000261652.7
PM5
Other missense variant is known to change same aminoacid residue: Variant chr17-16948872-C-T is described in ClinVar as [Likely_pathogenic]. Clinvar id is 645207.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
PP5
Variant 17-16948873-A-G is Pathogenic according to our data. Variant chr17-16948873-A-G is described in ClinVar as [Conflicting_classifications_of_pathogenicity, risk_factor]. Clinvar id is 5302.We mark this variant Likely_pathogenic, oryginal submissions are: {Likely_pathogenic=13, Pathogenic=12, Uncertain_significance=4, Likely_benign=1, risk_factor=1, not_provided=1}. Variant chr17-16948873-A-G is described in Lovd as [Likely_pathogenic]. Variant chr17-16948873-A-G is described in Lovd as [Pathogenic].
BP4
Computational evidence support a benign effect (MetaRNN=0.23062569). . Strength limited to SUPPORTING due to the PP5.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| TNFRSF13B | NM_012452.3 | c.310T>C | p.Cys104Arg | missense_variant | 3/5 | ENST00000261652.7 | NP_036584.1 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| TNFRSF13B | ENST00000261652.7 | c.310T>C | p.Cys104Arg | missense_variant | 3/5 | 1 | NM_012452.3 | ENSP00000261652 | P2 |
Frequencies
GnomAD3 genomes 0.00392 AC: 597AN: 152216Hom.: 4 Cov.: 32
GnomAD3 genomes
AF:
AC:
597
AN:
152216
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00350 AC: 879AN: 251490Hom.: 3 AF XY: 0.00343 AC XY: 466AN XY: 135918
GnomAD3 exomes
AF:
AC:
879
AN:
251490
Hom.:
AF XY:
AC XY:
466
AN XY:
135918
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00560 AC: 8186AN: 1461892Hom.: 28 Cov.: 35 AF XY: 0.00533 AC XY: 3875AN XY: 727246
GnomAD4 exome
AF:
AC:
8186
AN:
1461892
Hom.:
Cov.:
35
AF XY:
AC XY:
3875
AN XY:
727246
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome 0.00392 AC: 597AN: 152334Hom.: 4 Cov.: 32 AF XY: 0.00388 AC XY: 289AN XY: 74502
GnomAD4 genome
AF:
AC:
597
AN:
152334
Hom.:
Cov.:
32
AF XY:
AC XY:
289
AN XY:
74502
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
22
ALSPAC
AF:
AC:
28
ESP6500AA
AF:
AC:
8
ESP6500EA
AF:
AC:
46
ExAC
AF:
AC:
390
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Conflicting classifications of pathogenicity; risk factor
Submissions summary: Pathogenic:37Uncertain:5Benign:1Other:2
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
Immunodeficiency, common variable, 2 Pathogenic:17Uncertain:2Other:1
| Likely pathogenic, criteria provided, single submitter | clinical testing | Rady Children's Institute for Genomic Medicine, Rady Children's Hospital San Diego | - | This is a recurrent variant that has been reported as homozygous, compound heterozygous, and heterozygous change in individuals with common variable immunodeficiency (CVID) and in unaffected control individuals (PMID: 23237420, 17392797, 20156508, 24051380, 16007086, 16007087, 22884984). A study of 844 cases with CVID and 3924 controls found the p.Cys104Arg variant significantly enriched in cases versus controls (OR 5.60, CI 2.99-10.51, p=3.9 x 10-8) (PMID: 17392797). Further, a meta-analysis of 1,439 CVID patients and 3,558 controls confirmed enrichment of this variant in CVID cases versus controls (p < 10-5) (PMID: 22884984). In-vitro studies showed that the variant, which is located in the transmembrane (TM) domain of TACI, disrupts NF-kB/NF-AT signaling and leads to defective B-cell proliferation in response to stimulation (PMID: 21419480, 23237420, 19605846). It is present in the heterozygous state in the gnomAD population database at a frequency of 0.35% (983/282890) and in the homozygote state in 4 individuals. The c.310T>C (p.Cys104Arg) variant affects a highly conserved amino acid and is predicted by multiple in silico tools to have a deleterious effect on protein function. Based on the available evidence, the c.310T>C (p.Cys104Arg) variant is classified as Likely Pathogenic. - |
| Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | - | - - |
| Likely pathogenic, criteria provided, single submitter | clinical testing | Knight Diagnostic Laboratories, Oregon Health and Sciences University | Sep 06, 2019 | - - |
| Pathogenic, no assertion criteria provided | clinical testing | Molecular Genetics Laboratory, BC Children's and BC Women's Hospitals | Aug 13, 2024 | - - |
| risk factor, criteria provided, single submitter | clinical testing | Center of Genomic medicine, Geneva, University Hospital of Geneva | Jun 07, 2017 | - - |
| Uncertain significance, criteria provided, single submitter | clinical testing | Suma Genomics | - | - - |
| Likely pathogenic, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center | Sep 22, 2024 | - - |
| Likely pathogenic, criteria provided, single submitter | clinical testing | Laboratory of Medical Genetics, National & Kapodistrian University of Athens | Oct 06, 2021 | PM2, PM5, PP3, PP5 - |
| Likely pathogenic, criteria provided, single submitter | clinical testing | Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein | Dec 22, 2022 | ACMG classification criteria: PS3 supporting, PM3 moderated, PP1 moderated, PP3 supporting - |
| Pathogenic, criteria provided, single submitter | clinical testing | 3billion | Jan 03, 2022 | Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000005302, PS1_S). Functional studies provide strong evidence of the variant having a damaging effect on the gene or gene product (PMID: 21419480, 20889194, PS3_S). A different missense change at the same codon (p.Cys104Tyr) has been reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000645207, PM5_M). In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.919, 3CNET: 0.974, PP3_P). Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline. - |
| Pathogenic, criteria provided, single submitter | clinical testing | Institute of Immunology and Genetics Kaiserslautern | Jul 02, 2024 | ACMG Criteria: PS3, PS4, PM1, PM3, PM5, PP1, PP3, PP5; Variant was found in heterozygous state - |
| Pathogenic, criteria provided, single submitter | clinical testing | Mendelics | May 04, 2022 | - - |
| Likely pathogenic, criteria provided, single submitter | clinical testing | UCLA Clinical Genomics Center, UCLA | Jul 15, 2014 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University of Leipzig Medical Center | Dec 03, 2020 | - - |
| Likely pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 31, 2024 | This sequence change replaces cysteine, which is neutral and slightly polar, with arginine, which is basic and polar, at codon 104 of the TNFRSF13B protein (p.Cys104Arg). This variant is present in population databases (rs34557412, gnomAD 0.5%), and has an allele count higher than expected for a pathogenic variant. This missense change has been observed in individual(s) with common variable immunodeficiency (CVID) (PMID: 16007087, 17392797, 19779048, 22697072, 24051380, 27123465). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 5302). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt TNFRSF13B protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects TNFRSF13B function (PMID: 16007087, 20889194, 21419480, 21458042, 23237420, 24051380). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. - |
| Established risk allele, no assertion criteria provided | research | Department of Pathology and Laboratory Medicine, Sinai Health System | - | The TNFRSF13B c.310T>C (p.Cys104Arg) variant has been reported in >50 homozygous, heterozygous, and compound heterozygous individuals with common variable immune deficiency (CVID), as well as in multiple healthy individuals (Salzer_2009_PMID: 18981294; Barroeta Seijas_2012_PMID: 22697072; Martinez-Gallo_2013_PMID: 23237420; Lee_2010_PMID: 20889194; Pulvirenti_2016_PMID: 27123465; Freiberger_2012_PMID: 22884984). In addition, this variant segregated with disease in at least 13 members from 7 families; however, asymptomatic homozygous and heterozygous family members were also identified, suggesting incomplete penetrance (Salzer_2009_PMID: 18981294; Barroeta Seijas_2012_PMID: 22697072; Martinez-Gallo_2013_PMID: 23237420; Koopmans_2013_PMID: 22983507). The variant was identified in dbSNP (ID: rs34557412) and ClinVar (classified as pathogenic by GeneDx and two other submitters, as likely pathogenic by Invitae and three other submitters, as uncertain significance by Laboratory for Molecular Medicine and five other submitters, as likely benign by Illumina and one other submitter, and as 'risk factor' by University Hospital of Geneva). The variant was identified in control databases in 983 of 282890 chromosomes (4 homozygous) at a frequency of 0.00347, and was observed at the highest frequency in the European (non-Finnish) population in 697 of 129190 chromosomes (freq: 0.005395) (Genome Aggregation Database March 6, 2019, v2.1.1). The p.C104 residue is conserved in mammals and computational analyses (MUT Assesor, PolyPhen-2, SIFT, MutationTaster, Revel, FATHMM, MetaLR, DANN) suggest that the variant may impact the protein. Furthermore, multiple in vitro functional studies and murine models reveal that this variants leads to decreased protein surface expression, decreased antibody response, and impaired ligand binding ability compared to wildtype (Salzer_2009_PMID: 18981294; Martinez-Gallo_2013_PMID: 23237420; Lee_2010_PMID: 20889194; Bacchelli_2011_PMID: 21458042). The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (Splice AI) do not predict a deleterious effect on splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more pathogenic role for this variant. This variant is classified as likely pathogenic - risk factor for common variable immunodeficiency. - |
| Pathogenic, no assertion criteria provided | literature only | OMIM | Jun 01, 2007 | - - |
| Likely pathogenic, criteria provided, single submitter | clinical testing | Greenwood Genetic Center Diagnostic Laboratories, Greenwood Genetic Center | Apr 26, 2022 | PS3 PM1 PP3 - |
| Uncertain significance, no assertion criteria provided | clinical testing | Clinical Genomics Laboratory, Stanford Medicine | Mar 24, 2020 | The p.Cys104Arg variant in the TNFRSF13B gene has been previously reported in the heterozygous, compound heterozygous, or homozygous state in many individuals with common variable immunodeficiency (CVID; Castigli et al., 2005; de Valles-Ibáñez et al., 2018; Martinez-Polmar et al., 2009; Salzer et al., 2005). The p.Cys104Arg variant has also been identified in 697/129,190 European chromosomes, including 3 homozygotes, by the Genome Aggregation Database (http://gnomad.broadinstitute.org/), indicating it may be a common, reduced penetrance allele. The p.Cys104Arg variant is relatively common in the general population, and case-control studies provide conflicting evidence for an association with antibody deficiency (Castigli 2005; de VallesIbanez 2018; Pan-Hammarström et al, 2007; Pulvirenti et al., 2016; Salzer et al., 2009). Functional studies have shown that this variant impairs ligand binding, B cell proliferation, and antibody responses (Castigli et al., 2005; Fried et al., 2011; Lee et al., 2010; Salzer et al., 2005). Computational tools predict that the p.Cys104Arg variant is deleterious; however, the accuracy of in silico algorithms is limited. These data were assessed using the ACMG/AMP variant interpretation guidelines. In summary, the significance of the p.Cys104Arg variant is uncertain; however, there is suspicion that this variant could be associated with common variable immunodeficiency due to functional studies and the predicted impact to the protein. Additional information is needed to resolve the significance of this variant. [ACMG evidence codes used: PS3_moderate; PP3] - |
| Likely pathogenic, criteria provided, single submitter | clinical testing | Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen | Dec 07, 2022 | - - |
not provided Pathogenic:13Uncertain:1Benign:1
| Uncertain significance, criteria provided, single submitter | clinical testing | Blueprint Genetics | Jun 26, 2017 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | AiLife Diagnostics, AiLife Diagnostics | Mar 09, 2022 | - - |
| Likely pathogenic, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital | Feb 06, 2024 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Nov 01, 2024 | TNFRSF13B: PP1:Strong, PM1, PS3:Moderate, PS4:Moderate - |
| Likely benign, flagged submission | clinical testing | Center for Pediatric Genomic Medicine, Children's Mercy Hospital and Clinics | Sep 25, 2017 | - - |
| Likely pathogenic, no assertion criteria provided | clinical testing | Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen | - | - - |
| Likely pathogenic, no assertion criteria provided | clinical testing | Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center | - | - - |
| Likely pathogenic, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Sep 27, 2023 | The TNFRSF13B c.310T>C; p.Cys104Arg variant (rs34557412) has been reported in patients diagnosed with common variable immunodeficiency, and the association with the disease was found to be statistically significant (odds ratio 4.16 (1.98-8.74); Pan-Hammarstrom 2007). Additionally, functional studies show that this variant disrupts protein signaling (Martinez-Gallo 2013, Salzer 2005). However, this variant does not always segregate with disease in families (Poodt 2009, Koopmans 2013) and the variant is often observed in clinically asymptomatic first-degree relatives and healthy controls (Barroeta Seijas 2012, Martinez-Pomar 2009). This variant is reported in ClinVar (Variation ID: 5302), and is found in the general population with an overall allele frequency of 0.35% (983/282890 alleles, including 4 homozygotes) in the Genome Aggregation Database. Based on available information, this variant is considered to be a pathogenic CVID-associated variant with variable penetrance, that may act in co-existence with other genetic and/or environmental factors (Koopmans 2013). Barroeta Seijas AB et al. The impact of TACI mutations: from hypogammaglobulinemia in infancy to autoimmunity in adulthood. Int J Immunopathol Pharmacol. 2012 Apr-Jun;25(2):407-14. PMID: 22697072. Koopmans et al. Clinical variability of family members with the C104R mutation in transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI). J Clin Immunol. 2013 33(1):68-73. PMID: 22983507. Martínez-Pomar N et al. Role of TNFRSF13B variants in patients with common variable immunodeficiency. Blood. 2009 Sep 24;114(13):2846-8. PMID: 19779048. Martinez-Gallo et al. TACI mutations and impaired B-cell function in subjects with CVID and healthy heterozygotes. J Allergy Clin Immunol. 2013 131(2):468-476. PMID: 23237420. Pan-Hammarstrom et al. Reexamining the role of TACI coding variants in common variable immunodeficiency and selective IgA deficiency. Nat Genet. 2007 39(4):429-30. PMID: 17392797. Poodt AE et al. TACI mutations and disease susceptibility in patients with common variable immunodeficiency. Clin Exp Immunol. 2009 Apr;156(1):35-9. PMID: 19210517. Salzer U et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet. 2005 Aug;37(8):820-8. PMID: 16007087. - |
| Likely pathogenic, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Apr 20, 2020 | DNA sequence analysis of the TNFRSF13B gene demonstrated a sequence change, c.310T>C, in exon 3 that results in an amino acid change, p.Cys104Arg. This sequence change has been described in the gnomAD database with a relatively high population frequency of 0.54% in European populations (dbSNP rs34557412). The p.Cys104Arg change affects a highly conserved amino acid residue located in a domain of the TNFRSF13B protein that is known to be functional. In-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL) provide contradictory results for the p.Cys104Arg substitution. The p.Cys104Arg change has been reported in the homozygous, compound heterozygous, and heterozygous states in many individuals affected with common variable immunodeficiency (CVID) (PMID: 16007087, 17392797, 22697072, 27123465, 24051380, 19779048). Individuals who are heterozygous for this sequence change have been reported with an increased number of autoreactive B-cells in the bone marrow (PMID: 24051380). This sequence has also been seen in the heterozygous state in multiple unaffected individuals, however functional studies on B cells of these individuals show impaired function compared to unaffected individuals without variants in TNFRSF13B (PMID: 23237420, 24051380). The p.Cys104Arg change has been reported to segregate with disease in several families; however, it appears to have reduced penetrance (PMID: 16007087, 19779048, 22983507, 22697072, 22884984, 23237420). Functional studies have demonstrated that this sequence change affects ligand binding and reduces protein expression (PMID: 16007087, 21419480, 23237420). This sequence change is predicted to confer an increased risk for the development of CVID and is may confer an increased risk for lymphoma. We interpret this change as likely pathogenic. - |
| Likely pathogenic, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, Amsterdam University Medical Center | - | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jan 10, 2022 | Reported previously in association with both autosomal dominant and autosomal recessive forms of CVID and immunoglobulin A deficiency; however, this variant is most commonly associated with autosomal recessive inheritance (Salzer et al., 2009; Barroeta Seijas et al., 2012; Speletas et al., 2013; Martinez-Gallo et al., 2013; Lucena et al., 2015); Published functional studies demonstrate C104R results in reduced surface expression and elimination of ligand binding, supporting a damaging effect (Lee et al., 2010; Fried et al., 2011); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 25326637, 24051380, 17392797, 30269248, 17492055, 26727773, 22983507, 22697072, 20889194, 23956760, 23237420, 16007086, 19210517, 16007087, 18981294, 22884984, 25174870, 21850030, 27123465, 26100089, 27577878, 16630947, 29146883, 29867916, 29555771, 29921932, 29114388, 30665703, 31681265, 31618753, 32499645, 32581362, 21419480, 34573280, 34426522, 34210994, 30755392, 33425813, 33258288, 32441320, 32531373, 33726816) - |
| Likely pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Oct 19, 2023 | - - |
| Pathogenic, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, University Medical Center Utrecht | - | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Sep 29, 2020 | PS3, PS4_moderate, PP3 - |
Immunodeficiency, common variable, 1 Pathogenic:1
| Likely pathogenic, no assertion criteria provided | clinical testing | Clinic of Clinical Immunology with Stem Cell Bank, Expert Centre for Rare Diseases - PID, University Hospital "Alexandrovska" | May 01, 2022 | - - |
Immune deficiency, familial variable Pathogenic:1
| Pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University of Leipzig Medical Center | Nov 27, 2023 | Criteria applied: PS4,PS3_MOD,PM1,PM5 - |
TNFRSF13B-related disorder Pathogenic:1
| Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Sep 27, 2024 | The TNFRSF13B c.310T>C variant is predicted to result in the amino acid substitution p.Cys104Arg. This variant has previously been reported to be causative for both autosomal dominant and autosomal recessive forms of common variable immunodeficiency type 2, although autosomal recessive inheritance is more common (Salzer et al. 2005. PubMed ID: 16007087; Romberg et al. 2013. PubMed ID: 24051380). However, the c.310T>C variant has been shown to exhibit incomplete penetrance (Pan-Hammarström et al. 2007. PubMed ID: 17392797; Barroeta Seijas et al. 2012. PubMed ID: 22697072). Functional studies have shown the p.Cys104Arg variant impairs TACI ligand binding and B-cell function (Romberg et al. 2015. PubMed ID: 26100089; Lee et al. 2010. PubMed ID: 20889194). This variant is reported in 0.54% of alleles in individuals of European (Non-Finnish) descent in gnomAD. This variant is interpreted as pathogenic. - |
Immunoglobulin A deficiency 2;C3150354:Immunodeficiency, common variable, 2 Pathogenic:1
| Likely pathogenic, criteria provided, single submitter | clinical testing | Center for Genomics, Ann and Robert H. Lurie Children's Hospital of Chicago | Nov 25, 2020 | TNFRSF13B:NM_012452.2:c.310T>C:p.Cys104Arg: This variant has been reported in the literature in numerous individuals with Combined Variable Immune Deficiency (CVID) in the heterozygous, homozygous and compound heterozygous state and is listed as the most common variant reported in association with this condition (Selected Publications: Salzer 2005 PMID:16007087, Berglund 2006 PMID:16630947, Pan-Hammarstrom 2007 PMID:17392797, Barroeta-Seijas 2012 PMID:22697072, Koopmans 2013 PMID:22983507, Martinez-Galllo 2013 PMID:23237420, Rudilla 2019 PMID:31681265). This variant has been identified to segregate with disease in multiple different family members, also in the heterozygous, compound heterozygous and homozygous state. However, this variant has been identified in multiple individuals who do not present with disease (including in the homozygous state) even within the same family, suggesting that this variant has significant reduced penetrance (Koopmans 2013 PMID:22983507, Martinez-Galllo 2013 PMID:23237420). This variant is present in 0.7% (109/15278) of Latino alleles, including 1 homozygote and is present at similar frequencies across different ethnicities in the Genome Aggregation Database (https://gnomad.broadinstitute.org/variant/17-16948873-A-G?dataset=gnomad_r3). This variant is present in ClinVar, with classifications ranging from Variant of Uncertain Significance (Uncertain significance) to Pathogenic (Variation ID:5302). Evolutionary conservation and computational predictive tools suggest that this variant may impact the protein. Numerous functional studies including mouse models have demonstrated the impact of this variant by reducing expression on the surface of B-cells, impairing bindings with BAFF and APRIL and defective antibody production (Salzer 2005 PMID:16007087, Lee 2010 PMID:20889194, Fried 2011 PMID:21419480, Martinez-Galllo 2013 PMID:23237420). In summary, this variant is classified as likely pathogenic based on extensive studies, but may be best considered in the context of a non-mendelian risk allele. - |
Severe SARS-CoV-2 infection, susceptibility to Pathogenic:1
| Likely pathogenic, no assertion criteria provided | clinical testing | Institute for Genomic Statistics and Bioinformatics, University Hospital Bonn | Mar 03, 2021 | This variant was observed in homozygous state in a child with a lethal course of covid-19. The child was also homozygous for a splice site variant in TBK1, that is associated to autoinflammatory disorder. Probably a combination of the deleterious homozygous missense mutation in TNFRSF13B and the homozygous splice site mutation in TBK1 in the presence of an autoinflammatory disease and its treatment regimen - might have promoted the severe disease course observed in the present case either alone or in concert. - |
Immunoglobulin A deficiency 2 Pathogenic:1
| Pathogenic, no assertion criteria provided | literature only | OMIM | Jun 01, 2007 | - - |
Common variable immunodeficiency Pathogenic:1
| Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Mar 31, 2020 | Variant summary: TNFRSF13B c.310T>C (p.Cys104Arg) results in a non-conservative amino acid change located in the TACI, cysteine-rich domain (IPR015384) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.0035 in 251490 control chromosomes in the gnomAD database, including 3 homozygotes. The observed variant frequency is considerably higher than the estimated maximal expected allele frequency for a pathogenic variant in TNFRSF13B causing Common Variable Immunodeficiency (CVID) phenotype, strongly suggesting that the variant is benign. c.310T>C has been reported in the literature (in heterozygous, compound heterozygous or homozygous state) in multiple individuals affected with CVID. Specifically, in terms of individuals heterozygous for the variant, some are reported with CVID, some are reported with CVID-related symptoms and minor clinical manifestations while a lot of others are reported as healthy without any clinical symptoms (e.g. Abolhassani_2019, Alachkar_2006, Berglund_2006, Castigli_2005, Koopmans_2013, Kralickova_2019, Martinez-Pomar_2009, Poodt_2009, Salzer_2005, Salzer_2009, Speletas_2011, Zhang_2007). Many compound heterozygous and homozygous individuals are reported affected with CVID (e.g. Castigli_2005, de Valles-Ibanez_2018, Koopmans_2013, Maffucci_2016, Martinez-Pomar_2009, Salzer_2005, Salzer_2009, Zhang_2007). Interestingly, among 4 homozygous individuals reported as asymptomatic in two studies, 2 of them were observed with low immunoglobulin plasma levels and 1 with severe hypogammaglobulinemia (Koopmans_2013, Martinez-Pomar_2009). Altogether, these data indicate that the variant is likely to be associated with disease and reveal a continuum spectrum of disease severity, ranging from the absence of clinical symptoms, minor clinical manifestations and moderate to severe forms of CVID. Additional genetic or environmental factors are likely to play a role in disease manifestation. Multiple experimental studies suggest the variant causes significant defects to protein function. Specifically, protein expression and ligand binding were demonstrated to be significantly diminished (Bacchelli_2011, Salzer_2005). Mice heterozygous and homozygous for the equivalent murine mutation (C76R) exhibited significant B-cell dysfunction with splenomegaly, marginal zone B-cell expansion, diminished immunoglobulin production and serological responses to T cell-independent antigen, and abnormal immunoglobulin synthesis (Bacchelli_2011). A study by Martinez-Gallo et al (2013) showed that both, CVID affected individuals and their unaffected family members with the variant in heterozygous or homozygous form, had impaired B-cell TACI expression, reduced ligand binding, and markedly defective upregulation of AID mRNA. The authors concluded that B cells of relatives of subjects with CVID who have mutations in TNFRSF13B but normal immune globulin levels still have detectable in vitro B-cell defects. Eight ClinVar submitters (evaluation after 2014) cite the variant with conflicting interpretations [pathogenic/likely pathogenic (n=3); risk factor (n=1); uncertain significance (n=2); likely benign (n=2)]. Based upon comprehensive review of a large quantity of evidence spanning more than a decade, the variant was classified as a pathogenic risk factor for CVID. - |
not specified Uncertain:1
| Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Jul 27, 2018 | proposed classification - variant undergoing re-assessment, contact laboratory - |
Clubfoot;C0013274:Patent ductus arteriosus;C0025990:Micrognathia;C0033785:Pseudoarthrosis;C0265677:Hemivertebrae;C0345375:Short femur;C0345394:Vertebral hypoplasia;C0410528:Skeletal dysplasia;C0432163:Vertebral segmentation defect;C0746102:Chronic lung disease;C1145670:Respiratory failure;C2112942:Preaxial foot polydactyly;C2981150:Cleft palate;C4021862:Absent epiphyses;C4025010:Coat hanger sign of ribs;C5441745:Abnormal pulmonary interstitial morphology Uncertain:1
| Uncertain significance, criteria provided, single submitter | clinical testing | Center for Personalized Medicine, Children's Hospital Los Angeles | - | - - |
Immunodeficiency, common variable, 1;C3150354:Immunodeficiency, common variable, 2 Other:1
| not provided, no classification provided | phenotyping only | GenomeConnect - Invitae Patient Insights Network | - | Variant interpreted as Likely pathogenic and reported on 04-25-2018 by Invitae. GenomeConnect-Invitae Patient Insights Network assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. Registry team members make no attempt to reinterpret the clinical significance of the variant. Phenotypic details are available under supporting information. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Uncertain
DANN
Benign
DEOGEN2
Pathogenic
D;D;.
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Benign
D
LIST_S2
Benign
T;T;T
M_CAP
Pathogenic
D
MetaRNN
Benign
T;T;T
MetaSVM
Pathogenic
D
MutationAssessor
Uncertain
.;M;.
MutationTaster
Benign
A;A;A;A
PrimateAI
Benign
T
PROVEAN
Pathogenic
.;D;.
REVEL
Pathogenic
Sift
Pathogenic
.;D;.
Sift4G
Pathogenic
D;D;D
Polyphen
1.0
.;D;D
Vest4
MVP
MPC
0.084
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at